Literature DB >> 24733750

Angiotensin (1-7) prevents angiotensin II-induced nociceptive behaviour via inhibition of p38 MAPK phosphorylation mediated through spinal Mas receptors in mice.

W Nemoto1, Y Ogata, O Nakagawasai, F Yaoita, T Tadano, K Tan-No.   

Abstract

BACKGROUND: We have recently demonstrated that intrathecal (i.t.) administration of angiotensin II (Ang II) induces nociceptive behaviour in mice accompanied by a phosphorylation of p38 mitogen-activated protein kinase (MAPK) mediated through Ang II type 1 (AT1 ) receptors. The N-terminal fragment of Ang II, Ang (1-7), plays a pivotal role in counterbalancing many of the well-established actions induced by Ang II. However, the role of Ang (1-7) in spinal nociceptive transmission remains unclear. Therefore, we examined whether i.t. administration of Ang (1-7) can inhibit the Ang II-induced nociceptive behaviour in mice.
METHODS: In the behavioural experiments, the accumulated response time of nociceptive behaviour consisting of scratching, biting and licking in conscious mice was determined during a 25-min period starting after i.t. injection. The distribution and localization of AT1 or Mas receptors were analysed using a MapAnalyzer and confocal microscope, respectively. Phosphorylation of p38 MAPK in the dorsal spinal cord was measured by Western blotting.
RESULTS: The nociceptive behaviour induced by Ang II was dose-dependently inhibited by the co-administration of Ang (1-7). The inhibitory effect of Ang (1-7) was reversed by the co-administration of A779, a Mas receptor antagonist. Western blot analysis showed that the increase in spinal p38 MAPK phosphorylation following the i.t. administration of Ang II was also inhibited by Ang (1-7), and the Ang (1-7) induced-inhibition was prevented by A779.
CONCLUSIONS: Our data show that the i.t. administration of Ang (1-7) attenuates an Ang II-induced nociceptive behaviour and is accompanied by the inhibition of p38 MAPK phosphorylation mediated through Mas receptors.
© 2014 European Pain Federation - EFIC®

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24733750     DOI: 10.1002/ejp.512

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  5 in total

Review 1.  Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22.

Authors:  Sadashiva S Karnik; Khuraijam Dhanachandra Singh; Kalyan Tirupula; Hamiyet Unal
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

Review 2.  Insights into Cardiovascular Defects and Cardiac Epigenome in the Context of COVID-19.

Authors:  Shreya Sarkar; Rwik Sen
Journal:  Epigenomes       Date:  2022-04-21

3.  The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarction.

Authors:  Juan Wang; Wen He; Liping Guo; Yin Zhang; Hui Li; Suxia Han; Difei Shen
Journal:  Mol Med Rep       Date:  2017-06-23       Impact factor: 2.952

4.  Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain.

Authors:  Brittany L Forte; Lauren M Slosky; Hong Zhang; Moriah R Arnold; William D Staatz; Meredith Hay; Tally M Largent-Milnes; Todd W Vanderah
Journal:  Pain       Date:  2016-12       Impact factor: 6.961

Review 5.  Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease.

Authors:  Devang M Patel; Madhura Bose; Mark E Cooper
Journal:  Int J Mol Sci       Date:  2020-03-23       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.